Zoo....I have said previously it would not surprise me if Purdue does not use this to try and broker a deal for Podras. I doubt so much Rexista as IPCI would probably need some assurance that Purdue would not just shelf the completion.
but all one needs to do is look at their filing and supplements. While they acknowledge the NDA filing they keep referring to IPCI's generic and even filed supplements to the case filing for ANDA supplement. looks like they are going to try smoke and mirror tactic trying to characterize Rexista as a generic which would be protected. the problem is as an NDA relying on its own technology and only using the Original formula of Oxy which patent has expired they have an uphill battel and in my opinion either just want to stall the launch as long as possible or put them ahead at the bargaining table. ie. you give us a 10 year license on Podras and we drop the case and give you X amount, or something to that effect.
News 
Market Data 
Discover 
